Myelodysplastic Syndromes (MDS) Clinical Trials

11 recruiting

Myelodysplastic Syndromes (MDS) Trials at a Glance

11 actively recruiting trials for myelodysplastic syndromes (mds) are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Early Phase 1 with 2 trials, with the heaviest enrollment activity in New York, Tianjin, and Beijing. Lead sponsors running myelodysplastic syndromes (mds) studies include Assistance Publique Hopitaux De Marseille, Beijing InnoCare Pharma Tech Co., Ltd., and Ascentage Pharma Group Inc..

Browse myelodysplastic syndromes (mds) trials by phase

Treatments under study

About Myelodysplastic Syndromes (MDS) Clinical Trials

Looking for clinical trials for Myelodysplastic Syndromes (MDS)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelodysplastic Syndromes (MDS) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelodysplastic Syndromes (MDS) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Acute Myelogenous LeukemiaMyelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.266 enrolled18 locationsNCT06656494
Recruiting
Phase 3

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953
Recruiting
Early Phase 1

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Myelodysplastic Syndromes (MDS)Precursor Cell Lymphoblastic Leukemia-LymphomaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic18 enrolled1 locationNCT06765876
Recruiting
Phase 2

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Chronic Myeloid LeukemiaAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)+2 more
St. Petersburg State Pavlov Medical University60 enrolled1 locationNCT07238712
Recruiting
Phase 3

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Myelodysplastic Syndromes (MDS)
Celgene665 enrolled143 locationsNCT04064060
Recruiting
Early Phase 1

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Multiple MyelomaLymphomaHematologic Malignancy+5 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins8 enrolled1 locationNCT06398457
Recruiting
Not Applicable

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

Multiple MyelomaLymphomaLeukemia+2 more
University of Nebraska88 enrolled1 locationNCT04898790
Recruiting
Not Applicable

Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies

Myelodysplastic Syndromes (MDS)Leukemia Acute Myeloid - AML
Assistance Publique Hopitaux De Marseille70 enrolled1 locationNCT06886425
Recruiting

Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes (MDS)
IRCCS Azienda Ospedaliero-Universitaria di Bologna60 enrolled1 locationNCT06764511
Recruiting
Phase 1

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc.102 enrolled14 locationsNCT04275518
Recruiting
Phase 2

Eltrombopag therapy for low platelets in patients on azacitidine treatment for myelodysplastic syndrome and acute myeloid leukaemia

Low marrow blast count acute myeloid leukaemia (AML)Myelodysplastic Syndromes (MDS)
Peter Mac Callum Cancer Centre25 enrolled1 locationACTRN12610000641099